High dose therapy of breast cancer: current status.

[1]  Y. Yen,et al.  High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Stewart,et al.  Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Armitage,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Erdkamp,et al.  Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Samuels,et al.  Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Perkins,et al.  Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Fairclough,et al.  Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Cornetta,et al.  Tandem autotransplantation for the treatment of metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Rodenhuis,et al.  High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. , 1995, British Journal of Cancer.

[13]  A. Rodger,et al.  ABC of Breast Diseases: Metastatic breast cancer , 1994, BMJ.

[14]  R. Livingston.  Dose intensity and high dose therapy. Two different concepts , 1994, Cancer.

[15]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[16]  R. Mick,et al.  High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. , 1994, Bone marrow transplantation.

[17]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .

[18]  D. Adkins,et al.  Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. , 1993, Bone marrow transplantation.

[19]  N. Davidson,et al.  Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.

[20]  C. Hudis,et al.  Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[23]  B. Hillner,et al.  Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. , 1992, JAMA.

[24]  D. Eddy.  High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[26]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[27]  C. Stidley,et al.  Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Hortobagyi,et al.  Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Gregory,et al.  Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.

[30]  G. Bonadonna,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Teicher,et al.  Bone marrow autotransplantation for solid tumors--prospects. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[33]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. V. Von Hoff,et al.  Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  T. Shea,et al.  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Weiner,et al.  Cryopreserved autologous marrow infusion following high dose cancer chemotherapy. , 1977, European journal of cancer.

[39]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[40]  C. Eggers,et al.  CANCER OF THE BREAST , 1941, Annals of surgery.

[41]  P. Goss,et al.  Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. , 1996, Journal of Clinical Oncology.

[42]  C. J. Williams,et al.  Introducing new treatments for cancer : practical, ethical and legal problems , 1992 .

[43]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Rosner,et al.  4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[46]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .